Lexeo Therapeutics, Inc. Common Stock
LXEOStock
$4.56+4.05%52W
Market Cap$362.77M
P/E—
Div yield—
Beta1.41
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-60.10%
Price vs S&P 500 (4W)-0.25%
VGM Score30.41
Market Capitalization$362.77M
Earnings Surprise History
Q1 26-0.25est. -0.32
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.41
4.41
4.44
4.44
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
LXEOLexeo Therapeutics, Inc. Common Stock | — | — | D | $4.56 |
| AMGNAmgen Inc | C | C | C | $371.58 |
| GILDGilead Sciences Inc | C | B | C | $136.30 |
| ARGXargenx SE American Depositary Shares | D | A | B | $857.97 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| BIIBBiogen Inc. Common Stock | B | D | B | $208.92 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.56 |
| MRNAModerna, Inc. Common Stock | D | B | B | $63.15 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $171.55 |
| EXELExelixis Inc | C | B | B | $55.68 |
| TECHBio-Techne Corp. | D | C | B | $71.77 |
About
Lexeo Therapeutics is a clinical-stage biopharmaceutical company focused exclusively on developing gene therapies for hereditary and acquired genetic diseases with high unmet medical needs. The company applies genetic medicine approaches to address conditions with limited existing treatment options.